Cell MedX Corp., a biotech company dedicated to discovering, developing and marketing therapeutic and non-therapeutic products that encourage overall well-being, is excited to provide a corporate update to its shareholders. Certifications The Company obtained a Certificate of Conformity for the ebalance Pro device (the "Device") from LabTest Certification Inc. in the fiscal year 2019. The tests carried out for accreditation qualified the device as a device of Class A and Class B. Class A enables the device to be used in professional environments, including physicians, clinics, and hospitals; Class B enables an end-user to use the device at home. The company worked with ICON plc to prepare a 510k application to the US FDA Cell MedX is currently able to market the device as a wellness product in Canada without making any medical allegations. As of 1 January 2019, all suppliers of medical devices had to update their prior ISO certifications to comply with the new MDSAP norms for sale in Canada. Manufacturing Upon obtaining the Conformity Certificate, the Company worked with its Canadian manufacturing plant operated by NDS Electronic Solutions Inc. ("NDS") to produce the equilibrium equipment. The first 100 Canadian produced equilibrium systems were effectively finished in the third quarter of the companys fiscal year 2019, based on fresh results that improved the equilibrium equipment. Sales Representatives In the first quarter of its Fiscal 2020 the Company arrived into agreements with two people ("Sales Representatives") to market and sell the Devices in Canada. Private Placement On May 30th, 2019, the Company reported a non-brokered private placement offer (the Offering ) for up to 6,250,000 units at a fixed price of $0.12 per unit for up to $750,000. Each unit sold under the Offering consisted of one common share of the Company and one share bought the warrant (the "Warrant") which expired on the second anniversary of the date of issuance of the Warrant and could be exercised in one share of the Companys common stock at $0.20 per share.
Tags : Canada, Cell MedX Corp, US FDA, NDS Electronic Solutions Inc.,